Cancer gene therapy: Prospects of using human sodium iodide symporter gene in non-thyroidal cancer

S. Dutta, A. De
{"title":"Cancer gene therapy: Prospects of using human sodium iodide symporter gene in non-thyroidal cancer","authors":"S. Dutta, A. De","doi":"10.4103/2349-3666.240655","DOIUrl":null,"url":null,"abstract":"Gene therapy is one of the promising therapeutic strategies evolved rapidly in the frontier of translational biology in cancer. To overcome the off target effect of conventional cancer therapies it is the most flourishing approach in present epoch. Various researches in this context are ongoing to eradicate devastating cancer cells with minimal or no side effects. Of the various gene therapy protocols developed, a set of genes called suicide genes, are being actively pursued as potential strategy. Briefly, this strategy involves tumor targeted delivery of a therapy/reporter gene to convert a systematically administered pro-drug into a cytotoxic drug which in turn induces tumor cell death. Additionally, advancement in small animal imaging modalities facilitates real-time monitoring of the delivered transgene by using appropriate imaging probe developed against the transgene. Non-invasive monitoring helps to realize precise transgene delivery and also aid to understand therapy response. In this background, we have reviewed potential suicide genes frequently explored for cancer treatment, which supports both diagnostic and therapeutic applications with special emphasis on sodium iodide symporter (NIS). Apart from its natural expression in thyroid, NIS protein expression has raised the possibility of using radioiodide therapy and diagnosis in few non-thyroidal cancers as well. In this review, we also covered various challenges to get NIS gene therapeutics from bench to bedside in various non-thyroidal cancers.","PeriodicalId":34293,"journal":{"name":"Biomedical Research Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Research Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2349-3666.240655","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Gene therapy is one of the promising therapeutic strategies evolved rapidly in the frontier of translational biology in cancer. To overcome the off target effect of conventional cancer therapies it is the most flourishing approach in present epoch. Various researches in this context are ongoing to eradicate devastating cancer cells with minimal or no side effects. Of the various gene therapy protocols developed, a set of genes called suicide genes, are being actively pursued as potential strategy. Briefly, this strategy involves tumor targeted delivery of a therapy/reporter gene to convert a systematically administered pro-drug into a cytotoxic drug which in turn induces tumor cell death. Additionally, advancement in small animal imaging modalities facilitates real-time monitoring of the delivered transgene by using appropriate imaging probe developed against the transgene. Non-invasive monitoring helps to realize precise transgene delivery and also aid to understand therapy response. In this background, we have reviewed potential suicide genes frequently explored for cancer treatment, which supports both diagnostic and therapeutic applications with special emphasis on sodium iodide symporter (NIS). Apart from its natural expression in thyroid, NIS protein expression has raised the possibility of using radioiodide therapy and diagnosis in few non-thyroidal cancers as well. In this review, we also covered various challenges to get NIS gene therapeutics from bench to bedside in various non-thyroidal cancers.
肿瘤基因治疗:利用人碘化钠同转运体基因治疗非甲状腺癌的前景
基因治疗是在肿瘤转化生物学研究的前沿迅速发展起来的有前景的治疗策略之一。为了克服常规肿瘤治疗的脱靶效应,它是当今最蓬勃发展的方法。在此背景下,各种各样的研究正在进行中,以最小或没有副作用的方式根除毁灭性的癌细胞。在已开发的各种基因治疗方案中,一组被称为自杀基因的基因正被积极地作为潜在的策略进行研究。简而言之,该策略涉及肿瘤靶向递送治疗/报告基因,将系统给药的前药转化为细胞毒性药物,进而诱导肿瘤细胞死亡。此外,小动物成像方式的进步通过使用针对转基因开发的适当成像探针,促进了对传递的转基因的实时监测。非侵入性监测有助于实现精确的转基因传递,也有助于了解治疗反应。在此背景下,我们回顾了癌症治疗中经常发现的潜在自杀基因,这些基因支持诊断和治疗应用,特别强调了碘化钠同调体(NIS)。除了在甲状腺中自然表达外,NIS蛋白的表达也提高了在少数非甲状腺癌中使用放射性碘治疗和诊断的可能性。在这篇综述中,我们还涵盖了将NIS基因疗法从实验室应用到临床治疗各种非甲状腺癌的各种挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信